697 AN OPEN-LABEL, COMPARATIVE, MULTICENTRE STUDY OF PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN IN THE TREATMENT OF PATIENTS CHRONICALLY INFECTED WITH HCV/HBV OR HCV ALONE

C. -J. Liu,W. -L. Chuang,C. -M. Led,S. -S. Wu,L. -Y. Liao,H. -T. Kuo,Y. -C. Chao,C. -L. Chen,P. -J. Chen,D. -S. Chen

DOI: https://doi.org/10.1016/s0168-8278(08)60699-6

IF: 25.7

2008-01-01

Journal of Hepatology

Abstract:Background and Aims: Coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is common in areas with a high endemic level of both infections.Coinfected patients have more severe liver disease and an increased risk of hepatocellular carcinoma than mono-infected patients.Interferon + ribavirin for 48 weeks in patients with HCV/HBV coinfection demonstrated an HCV sustained viral response (SVR) comparable to that observed in HCV mono-infected patients.Here we present results of a multicentre study with peginterferon-based combination therapy in Taiwan.Methods: Eligible patients had serum ALT 1.5 X ULN and HCV RNA 100,000 copies/mL, with (n = 161) or without (n = 160) detectable HB-sAg.Patients with HCV genotype 1 received 48 weeks of peginterferon alfa-2a plus 1000-1200 mg ribavirin.Patients with HCV genotype non-1 received 24 weeks of peginterferon alfa-2a plus 800 mg ribavirin.The primary efficacy endpoint was sustained HCV RNA clearance (<25 IU/mL) 24 weeks post-treatment (SVR).Secondary endpoints were HBV viral response (<1000 copies/mL), ALT normalisation and HBsAg clearance at end of treatment and 24 weeks post-treatment.Results: HCV SVR was achieved in 73% and 86% of coinfected patients, and in 77% and 88% of monoinfected patients with genotype 1 and genotype non-1 HCV, respectively.68/145 coinfected patients (47%) had detectable HBV DNA at baseline; of these, 56% had undetectable HBV DNA (<1,000 copies/mL) at 24 weeks post-treatment.17/77 patients with undetectable HBV DNA at baseline suffered a rebound at 24 weeks post-treatment.No rebound was associated with an elevation of serum ALT >200 IU/mL, and most of these patients had achieved an HCV SVR.10% of coinfected patients had cleared HBsAg at 24 weeks post-treatment.More monoinfected patients achieved ALT normalisation than coinfected patients 24 weeks post treatment; 70% vs 62% and 78% vs 67% with HCV genotype 1 and genotype non-1, respectively.Conclusion: Combination therapy of peginterferon alfa-2a and ribavirin is effective for treatment of patients dually infected with HCV and HBV.Importantly, a substantial proportion of the dually infected patients achieved HBsAg clearance -an important indicator of long-term treatment success.